2013-02-13 08:33:04 -

Stockholm, Sweden, 13 February 2013 - Sobi (STO: Sobi) announced that it has
entered into a distribution agreement with PharmaSwiss to market the products
Megace®, Monopril®, Cefzil® and Duricef® approved for the treatment of
indications within the oncology, cardio-vascular and anti-infective therapy
areas. Under the terms of the agreement, Sobi will have distribution rights in
Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden,
Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal, and
Luxembourg. All products are approved within the Sobi territory, where sales in
2012 were approximately SEK 120 million (EUR 14 million).  Sobi expects to
initiate distribution for the portfolio by the end of the first quarter 2013.


Anders Edvell, Vice President and Head of Partner Products at Sobi, said: "We
have built a unique European platform with Partner Products   to support the
complex clinical and reimbursement requirements of niche and specialty
products.  We are delighted to be able to provide patients and physicians with
this portfolio of important treatment options, and to welcome PharmaSwiss as a
new partner."


About Megace® (megestrol):  Megace is a progestogen hormone drug is indicated
for the treatment of certain hormone-dependent neoplasms such as breast cancer.


About Monopril® (fosinopril):  Monopril is an angiotensin converting enzyme
(ACE) inhibitor indicated for treatment of hypertension and congestive heart
failure.


About Cefzil® (cefprozil):  Cefzil is a broad-spectrum cephalosporin antibiotic
indicated for the treatment of mild to moderate infections.

About Duricef® (cefadroxil):  Duricef is a cephalosporin antibiotic indicated
for the treatment of urinary tract infections, skin infections, pharyngitis
and/or tonsillitis, where the infections are caused by susceptible strains of
designated microorganisms.

About Sobi Partner Products
Sobi Partner Products (SPP) is a business unit within Sobi which offers a unique
commercial platform for partners with niche and specialty products. SPP provides
extensive knowledge and local experience through our direct presence across EU,
Eastern Europe, Russia, Middle East and North Africa.  We apply an integrated
commercial, medical, and market access approach to products which address
important unmet needs, working from named patient use (NPU) programs through to
reimbursement and commercialization, primarily in the Centre of Expertise
setting. The key SPP therapeutic areas are Oncology, Hematology, Infectious
Diseases, and Emergency Medicines & Antidotes.


About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market more than
40 specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9 billion (€
214 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.


Contact at Sobi
Anders Edvell - Vice President and Head of Partner Products
Phone: +46 8 697 2000


Jorgen Winroth - Vice President Investor Relations
Phone: +46 8 6973427

The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on February 13, 2013 at 08:30 a.m. CET.

Sobi Press Release on February 13, 2013, in PDF format: 
 hugin.info/134557/R/1677552/547139.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1677552]